Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

NCT03213587 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Apatinib

Sponsor

Zhejiang Cancer Hospital